Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCEstonia - Ongoing, recruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Estonia - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaEstonia - RecruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Acute Myeloid LeukemiaEstonia - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II, observer-blind, randomised, placebo-controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent genital herpes.
This study is testing a new treatment for herpes simplex (the virus that causes cold sores and genital herpes). It looks at how safe the treatment is, any side effects, and if it helps people with recurrent genital herpes, comparing it to a dummy treatment.
Herpes SimplexEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
This study is looking into a new treatment called itepekimab for people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It will compare the new drug to a dummy treatment to see if it helps reduce flare-ups of COPD and improves lung function in former smokers.
Chronic Obstructive Pulmonary DiseaseEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Estonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age
This study is testing a new mRNA flu vaccine for adults aged 50 and over. Researchers want to see how safe and effective it is compared to a standard flu jab. It aims to protect against the flu and understand how the body reacts to the new vaccine.
InfluenzaEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Estonia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
This study is testing a new medication called Sparsentan for people with a kidney condition called FSGS. It compares Sparsentan to an existing treatment (Irbesartan) to see how well it protects the kidneys and if it's safe over about two years.
Focal segmental glomerulosclerosis (FSGS)Estonia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsEstonia - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
Moderate to Severe Plaque PsoriasisEstonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Estonia - Not yet recruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisEstonia - Active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
Ulcerative ColitisEstonia - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisEstonia - Recruiting
Abbott Structural Heart Device Registry
This study looks at how well Abbott heart devices work in day-to-day hospital care. It helps make sure these devices are safe and effective for people with different heart conditions, like holes in the heart or valve problems, as they are used in real life.
Heart DiseasesASD - Atrial Septal DefectVSD - Muscular Ventricular Septal DefectPFO - Patent Foramen OvaleEstonia - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsEstonia - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaEstonia - RecruitingNot Applicable
Using light-based imaging to make heart stent treatment safer and more effective
This study looks at making heart attack treatment safer. It compares a new, clearer imaging method called OCT with standard X-rays to guide stent placement. We want to see if OCT helps doctors treat patients better and leads to improved recovery.
Optimizing percutaneous coronary intervention (PCI) for patients with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI)Estonia - AuthorisedPhase I and Phase II (Integrated)- Other
Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and taxane-resistant Prostate cancer (ChemSABR Prostate)
This study is for men with prostate cancer that hasn't responded to usual treatments. It's testing a new approach using chemotherapy drugs (vinorelbine and cisplatin) followed by special radiation therapy (SABR). Researchers want to see if this combination is safe and effective.
prostate cancerEstonia - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.
This study looks at a new drug, GSK4524101, combined with an existing cancer drug, niraparib (Zejula), for adults with solid tumours. It aims to find a safe dose and see how well the combination shrinks tumours and manages cancer.
NeoplasmsEstonia - Active not recruitingPHASE3
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
This study is looking at an RSV vaccine for people aged 60 and over. It aims to find the best time for repeat vaccination, understand long-term protection, and give the vaccine to people who previously received a dummy treatment.
Respiratory Syncytial Virus InfectionsEstonia - AuthorisedTherapeutic use (Phase IV)
Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)
This study looks at how well people who are overweight tolerate a medicine called semaglutide. We want to see if adding another medicine helps reduce sickness (nausea) during the first few days of taking semaglutide for weight management.
Overweight and obesityEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
This study is testing a new medicine, AVP-786, for people with Alzheimer's disease who experience agitation. It aims to see if the medicine can help reduce agitation and if it's safe to use. Some people will get the medicine, and others will get a dummy pill.
Agitation in Patients With Dementia of the Alzheimer's TypeEstonia - Active not recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study looks at a new medicine called ocrelizumab for children and teenagers aged 10-17 with a type of MS called relapsing-remitting multiple sclerosis (RRMS). It compares ocrelizumab to an existing medicine, fingolimod, to see how safe and effective it is over a period of time.
Relapsing-Remitting Multiple SclerosisEstonia - Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Fabry disease over time, including pregnant women. It helps doctors better understand the disease and improve care, without giving any new treatments. It's about observing, not experimenting.
Fabry DiseaseEstonia - Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study looks at how skin conditions like alopecia areata, vitiligo, and hidradenitis suppurativa affect daily life for teenagers and adults. Researchers want to understand the challenges these conditions bring to people all over the world.
Non-Segmental Vitiligo (NSV)Alopecia AreataHidradenitis SuppurativaEstonia - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
PneumoniaEstonia - Active not recruitingPHASE3
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
This study is testing a new medicine, concizumab, for people with haemophilia A or B, with or without 'inhibitors'. It aims to see if concizumab can prevent bleeds and if it's safe to use. Participants will inject the medicine daily under their skin.
Haemophilia A and B With and Without InhibitorsEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Effect of ALlopurinol in addition to hypothermia for hypoxicischemic Brain Injury on Neurocognitive Outcome
This study is looking at whether a medicine called allopurinol, when given with usual cooling treatment, can help babies who have suffered a specific type of brain injury around birth. Researchers want to see if it improves their development and reduces serious problems by age two.
Brain injury termed “hypoxic-ischemic encephalopathy” (HIE) as a result of various events during labour and childbirth such as placental abruption, uterine rupture, umbilical cord complications, etc.)Estonia - Active not recruitingPHASE2
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
This study looks at new drug combinations for advanced bowel cancer that has specific genetic markers (MSI-H or dMMR). It compares these combinations with existing treatments to see if they are more effective and safe for patients.
Colorectal CancerEstonia - Recruiting
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
This study looks at how safe a medicine called maribavir is for adults with serious kidney problems and a CMV germ infection after they've had an organ transplant. We're reviewing existing medical records to understand its effects without changing anyone's care.
Cytomegalovirus (CMV)Kidney DiseaseKidney FailureEstonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
This study is testing a new medicine, SCD-044, for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if different doses of this medicine are safe and help improve eczema symptoms by a lot.
atopic dermatitisEstonia - AuthorisedPhase II and Phase III (Integrated)
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
This study is looking at a new eye treatment, EYE201, for a serious eye condition called wet age-related macular degeneration (wet AMD). It compares EYE201 to an existing treatment, aflibercept, to see which is better at improving vision over one year.
Neovascular age-related macular degeneration (NVAMD)Estonia - Active not recruitingPHASE2
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
This study is looking into a new medication called Rosnilimab for people with moderate to severe rheumatoid arthritis. We want to see if it's safe, and if it helps reduce symptoms, compared to a dummy treatment.
Rheumatoid ArthritisEstonia - Active not recruitingPHASE3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
This study is looking at a new medicine called milvexian to see if it can help prevent another stroke in people who have recently had a mini-stroke or a type of stroke called an ischemic stroke.
Ischemic Stroke; Ischemic Attack, TransientEstonia - Active not recruitingPHASE2
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
This study compares two medicines for children born small who haven't caught up in height. One is a new weekly injection (somapacitan), and the other is a daily injection already available (Norditropin®). It aims to see how well they help children grow.
Short Stature Children Born Small for Gestational Age (SGA)Estonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
This study looks at new inhaled medications for people with a type of lung disease called COPD. It aims to see if these new medicines can help reduce flare-ups, improve breathing, and make everyday life better.
Chronic Obstructive Pulmonary Disease (COPD)Estonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Estonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
This study is testing a new medicine, Tildacerfont, for adults with a condition called Classic Congenital Adrenal Hyperplasia (CAH). Doctors want to see if it helps reduce certain hormone levels and if it's safe to use.
Classic Congenital Adrenal HyperplasiaEstonia - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseEstonia - RecruitingPHASE2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study looks at whether a new medicine, BI 764198, can help adults and teenagers with certain kidney problems. It compares the new medicine to a dummy pill to see if it reduces protein in the urine and improves kidney health.
Proteinuric Kidney DiseasesEstonia - Active not recruitingPHASE3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study looks at a new medicine called ziltivekimab for people with heart failure and inflammation. It aims to see if monthly injections of ziltivekimab can help, compared to a dummy medicine, over a few years.
Heart FailureEstonia - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Estonia - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerEstonia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Global, Randomized, Modified Double-Blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine in Adults 60 Years of Age and Older.
This study is testing a new vaccine for older adults (60+) against two common winter bugs: Respiratory Syncytial Virus (RSV) and human Metapneumovirus (hMPV). It aims to see if the vaccine prevents these illnesses and is safe.
Respiratory Syncytial Virus and Human MetapneumovirusEstonia